Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
about
Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent modelsA lectin isolated from bananas is a potent inhibitor of HIV replicationBroad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family CoronaviridaeBiologically Active Metabolites Synthesized by Microalgae.Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virusInvestigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidateDrugs in development for influenza.Virulence determinants of pandemic influenza viruses.Mutagenesis of surfactant protein D informed by evolution and x-ray crystallography enhances defenses against influenza A virus in vivoEmerging antiviral strategies to interfere with influenza virus entry.Newer influenza antivirals, biotherapeutics and combinations.Algal lectins as potential HIV microbicide candidatesHow to approach and treat viral infections in ICU patientsEngineering a therapeutic lectin by uncoupling mitogenicity from antiviral activityCarbohydrate recognition by the antiviral lectin cyanovirin-N.Development of novel entry inhibitors targeting emerging viruses.Lectin-Glycan Interaction Network-Based Identification of Host Receptors of Microbial Pathogenic AdhesinsAnimal models for the study of influenza pathogenesis and therapy.Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery.Drugs to cure avian influenza infection--multiple ways to prevent cell deathAntiviral strategies against influenza virus: towards new therapeutic approaches.Antiviral drug discovery: broad-spectrum drugs from nature.HIV-1 and its resistance to peptidic carbohydrate-binding agents (CBAs): an overview.Human lectins and their roles in viral infections.Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza.Antiviral lectins: Selective inhibitors of viral entry.An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.Preparation of monoPEGylated Cyanovirin-N's derivative and its anti-influenza A virus bioactivity in vitro and in vivo.Enhancement of antiviral activity of collectin trimers through cross-linking and mutagenesis of the carbohydrate recognition domain.The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins.Antiviral activity of recombinant cyanovirin-N against HSV-1.Regulation of influenza virus-caused oxidative stress by Kegan Liyan oral prescription, as monitored by ascorbyl radical ESR signals.The promising future of microalgae: current status, challenges, and optimization of a sustainable and renewable industry for biofuels, feed, and other products.
P2860
Q24610025-96894C68-9CA0-41BD-8D05-A6EFF2FACC00Q24629155-5A98D91C-E98F-4FFB-BA33-877C6E93D5F1Q24648487-6542CCB0-ED45-44CA-BF9C-C5D168CDB04FQ26784427-E58B3290-C7FA-485C-8245-012E229E7CABQ28084005-71BF8727-7B8A-47BF-BB3D-473B673A7B42Q28741890-7371615E-4456-4882-90B4-EDCFC6D855FCQ30391218-54D735C4-BBBD-4E37-966A-9B102C995BA3Q30398168-47A5282F-F9A3-4667-B917-D42068FC3E8EQ30407670-7AE57E9C-2E6A-43C3-8B3E-D2C0F3221C0BQ30432421-B0B6263E-6761-4E16-918D-DBE173AF40C9Q30456363-E10B36CC-B165-4EC3-B9EE-9959992DB2BEQ34291727-7CE22F69-AE3A-46C1-BD81-4BB88CF6464FQ34894660-86A35B9A-F3CF-4788-B8E2-B55C877EB10BQ36271352-47F3DB56-DB49-435C-910F-1A27E12459C4Q36492955-39FCA9E6-0DD1-4919-BC79-DAAD530EB66FQ36655280-242CFF19-4646-4762-AD0E-339A46EFDAD7Q37120236-C7D374E4-EA3C-4963-B452-19F262B72466Q37379466-82CD4FB2-772E-4CA1-978C-71C63280B3C8Q37767654-1424DF94-0751-453B-99CF-9313C8191B47Q38078403-A71F4A65-D055-4E2A-95A8-2BE7927761AAQ38148960-03C336BE-98B6-4EF4-ABF4-FE141331666DQ38202012-78F29D8B-3D36-43DA-BCF0-8B9E27D4DF40Q38260235-CF1DCADA-77F1-4962-81BC-905002CD4173Q38291704-BADC31FC-8FEB-4E19-A8F9-9C5E1A2942CFQ38340871-040E15B8-8EE2-4238-A20D-439197D0615BQ38384758-6638EB0D-2849-423E-8622-0691D478DF32Q38891044-9DFAFC16-F659-4158-B147-481F4DD4BC39Q40372317-B0CE036E-D7E8-4D30-82A8-E4536B33A391Q41465210-185BE0E0-BB8D-4DF4-9000-4EABFD421DE3Q42409222-B4C67DB6-B201-4489-82AD-D751EF2A4C8AQ42699742-73FD8742-CD6D-4555-9813-EFF94DDD4A0DQ42759444-C4919D6F-2868-450E-918E-009BC510D014Q43235804-D9E54B7F-878B-4118-BA5A-275BCCEF077FQ55234950-2F692F7E-195E-4732-B675-38E62E9C5A28
P2860
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@ast
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@en
type
label
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@ast
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@en
prefLabel
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@ast
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@en
P2093
P2860
P1433
P1476
Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.
@en
P2093
Barry R O'Keefe
Kevin W Bailey
Kirk R Gustafson
Larisa V Gubareva
Min-Hui Wong
Vasiliy P Mishin
P2860
P304
P356
10.1016/J.ANTIVIRAL.2008.06.003
P577
2008-07-02T00:00:00Z